The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?
A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
The group has the only approved cell-based cancer blood test in the world, but competing in an increasingly cutthroat market will be tough.
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.